
Anirban P Mitra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9825630/publications.pdf Version: 2024-02-01



ΔΝΙΔΒΛΝ Ρ ΜΙΤΟΛ

#	Article	IF	CITATIONS
1	Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. PLoS ONE, 2013, 8, e66855.	2.5	524
2	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. Journal of Urology, 2013, 190, 2047-2053.	0.4	280
3	Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification. Journal of Clinical Oncology, 2006, 24, 5552-5564.	1.6	263
4	Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer. Journal of Urology, 2014, 192, 50-56.	0.4	212
5	Molecular Pathogenesis and Diagnostics of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 251-285.	22.4	167
6	A Central Role for Long Non-Coding RNA in Cancer. Frontiers in Genetics, 2012, 3, 17.	2.3	150
7	Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Reviews in Urology, 2008, 10, 31-43.	0.9	137
8	A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases, 2014, 17, 64-69.	3.9	128
9	Molecular markers for bladder cancer: the road to a multimarker approach. Expert Review of Anticancer Therapy, 2007, 7, 1717-1727.	2.4	103
10	Factors influencing postâ€recurrence survival in bladder cancer following radical cystectomy. BJU International, 2012, 109, 846-854.	2.5	101
11	Generation of a Concise Gene Panel for Outcome Prediction in Urinary Bladder Cancer. Journal of Clinical Oncology, 2009, 27, 3929-3937.	1.6	98
12	Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 117-127.	1.6	87
13	Molecular markers in bladder cancer. World Journal of Urology, 2019, 37, 31-40.	2.2	86
14	Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU International, 2013, 112, E51-8.	2.5	82
15	p53 and retinoblastoma pathways in bladder cancer. World Journal of Urology, 2007, 25, 563-571.	2.2	75
16	Molecular screening for bladder cancer: progress and potential. Nature Reviews Urology, 2010, 7, 11-20.	3.8	70
17	Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles. European Urology, 2010, 57, 12-20.	1.9	64
18	The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer, 2006, 6, 159.	2.6	61

ANIRBAN P MITRA

#	Article	IF	CITATIONS
19	Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer. Seminars in Oncology, 2012, 39, 524-533.	2.2	61
20	Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget, 2013, 4, 600-609.	1.8	58
21	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e1-52.e9.	1.6	55
22	Molecular staging of bladder cancer. BJU International, 2005, 96, 7-12.	2.5	53
23	Molecular Biology of Bladder Cancer: Prognostic and Clinical Implications. Clinical Genitourinary Cancer, 2006, 5, 67-77.	1.9	46
24	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	46
25	A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage <scp>T</scp> 2 bladder cancer. BJU International, 2013, 111, 240-248.	2.5	45
26	Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder. Journal of Urology, 2016, 195, 493-498.	0.4	42
27	Outcomes After Urothelial Recurrence in Bladder Cancer Patients Undergoing Radical Cystectomy. Urology, 2014, 84, 1420-1426.	1.0	38
28	Molecular substratification of bladder cancer: moving towards individualized patient management. Therapeutic Advances in Urology, 2016, 8, 215-233.	2.0	38
29	Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology, 2009, 27, 9-20.	2.2	37
30	Strategies for molecular expression profiling in bladder cancer. Cancer and Metastasis Reviews, 2009, 28, 317-326.	5.9	36
31	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. Journal of Urology, 2016, 196, 1036-1041.	0.4	33
32	Combination of molecular alterations and smoking intensity predicts bladder cancer outcome . Cancer, 2013, 119, 756-765.	4.1	32
33	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Journal of Urology, 2022, 207, 302-313.	0.4	31
34	Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 201-215.	1.8	30
35	A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. European Journal of Cancer, 2013, 49, 3159-3168.	2.8	23
36	Primary Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2011, 135, 822-830.	0.7	21

ANIRBAN P MITRA

#	Article	IF	CITATIONS
37	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 48-56.	1.6	21
38	Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Review of Anticancer Therapy, 2010, 10, 1945-1954.	2.4	20
39	Principal component analysis based preâ€cystectomy model to predict pathological stage in patients with clinical organâ€confined bladder cancer. BJU International, 2013, 111, E167-72.	2.5	18
40	Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. The National Medical Journal of India, 2005, 18, 304-12.	0.3	18
41	Longâ€ŧerm outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. BJU International, 2013, 111, E37-42.	2.5	17
42	Radical cystectomy with superâ€extended lymphadenectomy: impact of separate vs <i>en bloc</i> lymph node submission on analysis and outcomes. BJU International, 2016, 117, 253-259.	2.5	17
43	Clinicopathologic Characteristics and OutcomesÂof Penile Cancer Treated at Tertiary Care Centers in the Western United States. Clinical Genitourinary Cancer, 2014, 12, 138-142.	1.9	15
44	Outcome in patients with exclusive carcinoma <i>in situ</i> (<scp>CIS</scp>) after radical cystectomy. BJU International, 2014, 113, 65-69.	2.5	13
45	Searching for novel therapeutics and targets: Insights from clinical trials. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 341-343.	1.6	12
46	Bladder and Urethra. , 2009, , 1079-1120.		10
47	Radical cystectomy and orthotopic urinary diversion in male patients with <scp>pT4a</scp> urothelial bladder carcinoma: Oncological outcomes. International Journal of Urology, 2013, 20, 1229-1233.	1.0	10
48	Pathological possibilities and pitfalls in detecting aggressive bladder cancer. Current Opinion in Urology, 2012, 22, 397-404.	1.8	9
49	Internal audit of an enhanced recovery after surgery protocol for radical cystectomy. World Journal of Urology, 2020, 38, 3131-3137.	2.2	9
50	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228.	1.9	8
51	Robotic adrenalectomy in the pediatric population: initial experience case series from a tertiary center. BMC Urology, 2020, 20, 155.	1.4	7
52	Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales?. Expert Review of Anticancer Therapy, 2011, 11, 849-852.	2.4	5
53	Molecular Prognostication in Bladder Cancer. Cancer Treatment and Research, 2018, 175, 165-191.	0.5	5
54	1911 FACTORS INFLUENCING LYMPH NODE YIELD DURING RADICAL CYSTECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY: SINGLE-INSTITUTION EXPERIENCE WITH A STANDARDIZED DISSECTION TEMPLATE. Journal of Urology, 2012, 187, .	0.4	3

ANIRBAN P MITRA

#	Article	IF	CITATIONS
55	2130 VALIDATION OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH HIGH RISK PATHOLOGICAL FEATURES POST-PROSTATECTOMY. Journal of Urology, 2013, 189, .	0.4	2
56	516 BLOOD LOSS DURING RADICAL CYSTECTOMY AND CONCOMITANT TRANSFUSIONS: INFLUENCING FACTORS AND IMPACT ON PATIENT OUTCOMES. Journal of Urology, 2013, 189, .	0.4	2
57	Perioperative complications and oncological outcomes following radical cystectomy among different racial groups: A long-term, single-center study. Canadian Urological Association Journal, 2020, 14, E493-E498.	0.6	2
58	Reply from Authors re: Joseph L. Chin. In Search of the Perfect Crystal Ball for Ta Urothelial Cancer. Eur Urol 2010;57:21–2. European Urology, 2010, 57, 23-24.	1.9	1
59	514 ENHANCED RECOVERY AFTER SURGERY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER. Journal of Urology, 2013, 189, .	0.4	1
60	Risk Factors and Molecular Features Associated with Bladder Cancer Development. Molecular Pathology Library, 2018, , 3-28.	0.1	1
61	Heterotopic Bone Formation in Clear Cell Renal Cell Carcinoma. Urology, 2020, 144, 13-14.	1.0	1
62	Intensified and Standardized Digital Communication with Cystectomy Patients as a Potentially Simple and Effective Modality for Early Detection of Postoperative Complications: Results from a Pilot Study. European Urology Open Science, 2020, 22, 3-8.	0.4	1
63	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. European Urology, 2021, 79, 428-429.	1.9	1
64	Enhanced recovery after cystectomy in patients with preoperative narcotic use. Canadian Urological Association Journal, 2021, 15, E563-E568.	0.6	1
65	Abstract 24: Diagnosing small round cell tumors using whole transcriptome expression profiling , 2013, , .		1
66	A CONCISE 4-GENE PANEL CAN PREDICT CLINICAL OUTCOME IN URINARY BLADDER CANCER. Journal of Urology, 2009, 181, 71-71.	0.4	0
67	560 COMBINATION OF MOLECULAR ALTERATIONS AND SMOKING INTENSITY PREDICTS BLADDER CANCER OUTCOME: A REPORT FROM THE LOS ANGELES CANCER SURVEILLANCE PROGRAM. Journal of Urology, 2012, 187, .	0.4	0
68	887 USING ARTIFICIAL INTELLIGENCE AND MACHINE-LEARNING ALGORITHMS WITH GENE EXPRESSION PROFILING TO PREDICT SUPERFICIAL BLADDER CANCER RECURRENCE AT INITIAL PRESENTATION. Journal of Urology, 2012, 187, .	0.4	0
69	1587 DIAGNOSTIC AND SURGICAL DELAYS IN BLADDER CANCER AND ITS IMPACT ON CLINICAL OUTCOME. Journal of Urology, 2012, 187, .	0.4	0
70	1276 A NOVEL PRECISION-ENGINEERED MEMBRANE MICROFILTRATION DEVICE FOR CAPTURE AND CHARACTERIZATION OF BLADDER CANCER CELLS IN URINE. Journal of Urology, 2012, 187, .	0.4	0
71	1751 OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR RECURRENT BLADDER CANCER FOLLOWING PRIOR PARTIAL CYSTECTOMY. Journal of Urology, 2012, 187, .	0.4	0
72	2230 EVALUATION OF A GENOMIC CLASSIFIER FOR IMPROVED RISK STRATIFICATION IN PROSTATE CANCER PATIENTS WITH SPECIFIC ADVERSE PATHOLOGIES AFTER SURGERY. Journal of Urology, 2013, 189, .	0.4	0

#	Article	IF	CITATIONS
73	2240 PERFORMANCE OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY. Journal of Urology, 2013, 189, .	0.4	0
74	1620 OVER DECADES, RADICAL CYSTECTOMY WITH EXTENDED LYMPHADENECTOMY PROVIDES PREDICTABLE OUTCOMES TO PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER - NOTWITHSTANDING BLADDER CANCER REMAINS AS DEADLY AS 30 YEARS AGO. Journal of Urology, 2013, 189, .	0.4	0
75	1255 EVOLVING TRENDS IN URINARY DIVERSION FOLLOWING RADICAL CYSTECTOMY: A SINGLE-INSTITUTION EXPERIENCE OVER 25 YEARS. Journal of Urology, 2013, 189, .	0.4	0
76	MP39-09 A COMBINATION OF GENOMIC MARKERS AND CLINICAL VARIABLES PROVIDES SUPERIOR PROGNOSTIC PERFORMANCE IN HIGH-RISK BLADDER CANCER FOLLOWING CYSTECTOMY. Journal of Urology, 2014, 191, .	0.4	0
77	MP61-15 IMPACT OF GENDER ON POST-CYSTECTOMY BLADDER CANCER OUTCOMES: DIFFERENCES IN OBSERVATIONS BETWEEN MATCHED AND UNMATCHED CASE-CONTROL APPROACHES. Journal of Urology, 2014, 191, .	0.4	0
78	MP61-20 PELVIC RECURRENCE FOLLOWING RADICAL CYSTECTOMY AND ITS IMPACT ON BLADDER CANCER OUTCOMES. Journal of Urology, 2014, 191, .	0.4	0
79	Pelvic hemangiopericytoma: A case report and review of the literature. Urology Case Reports, 2020, 32, 101247.	0.3	0
80	Bladder Cancer Tissue-Based Biomarkers. Société Internationale D'urologie Journal, 2021, 2, 53-71.	0.4	0
81	Robotic-assisted laparoscopic partial nephrectomy in a renal transplant. Urology Video Journal, 2021, 10, 100082.	0.2	0
82	Abstract 17: Prognostic value of coding and non-coding genomic meta-features in rhabdomyosarcoma , 2013, , .		0
83	Abstract 4973: Long non-coding RNA promotes metastatic behavior in Ewing sarcoma. , 2014, , .		0
84	Abstract 4730: Identification of novel prognostic signatures in rhabdomyosarcoma by whole transcriptome expression profiling: A discovery and validation study. , 2014, , .		0
85	Reply by Authors. Journal of Urology, 2022, 207, 313-313.	0.4	0
86	American Association for Cancer Research100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA. IDrugs: the Investigational Drugs Journal, 2009, 12, 339-41.	0.7	0